Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPSIS: STN1013600 for Presbyopia
NCT05665387Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ursodeoxycholic acid in presbyopia, sponsored by Santen Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05665387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665387.